Fluvoxamine Maleate interactions

Checked as Fluvoxamine in this data source.

Full monograph for Fluvoxamine Maleate Check it against another medicine

Medicines

561 documented

Severity

Mechanism

Medicines documented to interact with Fluvoxamine Maleate, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Almotriptan	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Aminophylline	Major	Metabolism	Coadministration with fluvoxamine may significantly increase the serum concentrations of theophylline and the associated risk of toxicity. The mechanism is…	16 sources — open the full entry
Amitriptyline Hydrochloride	Major	Metabolism	Coadministration with fluvoxamine may significantly increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is…	25 sources — open the full entry
Amitriptyline Hydrochloride + Chlordiazepoxide	Major	Metabolism	Coadministration with fluvoxamine may significantly increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is…2 documented mechanisms	36 sources — open the full entry
Bupropion Hydrochloride	Major	Metabolism	The use of bupropion is associated with a dose-related risk of seizures. The risk may be further increased when coadministered with other agents that can…	23 sources — open the full entry
Cilostazol	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active…	12 sources — open the full entry
Citalopram Hydrobromide	Major	Metabolism	Coadministration with CYP450 2C19 inhibitors may increase the plasma concentrations of citalopram, which is partially metabolized by the isoenzyme. Cases of QT…	9 sources — open the full entry
Clomipramine Hydrochloride	Major	Metabolism	Coadministration with fluvoxamine may significantly increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is…	25 sources — open the full entry
Clopidogrel + Aspirin	Major	Metabolism · Synergy	Coadministration with potent inhibitors of CYP450 2C19 may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation…2 documented mechanisms	59 sources — open the full entry
Clopidogrel Bisulphate	Major	Metabolism	Coadministration with potent inhibitors of CYP450 2C19 may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation…	17 sources — open the full entry
Cyclobenzaprine Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Desvenlafaxine Succinate	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Dextromethorphan + Bupropion	Major	Metabolism · Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…2 documented mechanisms	157 sources — open the full entry
Dextromethorphan + Phenylephrine + Triprolidine	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…2 documented mechanisms	178 sources — open the full entry
Dextromethorphan + Pseudoephedrine + Triprolidine	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…2 documented mechanisms	178 sources — open the full entry
Dextromethorphan Hydrobromide	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	134 sources — open the full entry
Dextromethorphan Hydrobromide + Guaifenesin	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	134 sources — open the full entry
Dextromethorphan Polistirex	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	134 sources — open the full entry
Diazepam	Major	Metabolism	One study has reported that fluvoxamine significantly decreases the clearance of diazepam and desmethyldiazepam in healthy volunteers. The mean half-life of…	41 sources — open the full entry
Diphenhydramine + Dextromethorphan + Levomenthol	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…2 documented mechanisms	178 sources — open the full entry
Doxepin (Oral)	Major	Metabolism	Coadministration with fluvoxamine may significantly increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is…	25 sources — open the full entry
Doxepin (Topical)	Major	Metabolism	Coadministration with fluvoxamine may significantly increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is…	25 sources — open the full entry
Duloxetine Hydrochloride	Major	Metabolism	Coadministration with fluvoxamine may significantly increase the plasma concentrations of duloxetine. The mechanism is fluvoxamine inhibition of duloxetine…	15 sources — open the full entry
Fentanyl Citrate	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Fluphenazine + Nortriptyline	Major	Metabolism · Synergy	Coadministration with fluvoxamine may significantly increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is…2 documented mechanisms	27 sources — open the full entry
Granisetron	Major	Synergy	Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs)…	16 sources — open the full entry
Guaifenesin + Dextromethorphan + Menthol	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	134 sources — open the full entry
Imipramine Hydrochloride	Major	Metabolism	Coadministration with fluvoxamine may significantly increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is…	25 sources — open the full entry
Iohexol	Major	Synergy	Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of…	5 sources — open the full entry
Iopamidol	Major	Synergy	Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of…	5 sources — open the full entry
Lasmiditan Hemisuccinate	Major	Synergy	Coadministration of lasmiditan and serotonergic agents may increase the risk of serotonin syndrome. Lasmiditan binds to the 5-HT(1F) receptor, where it…	5 sources — open the full entry
Levomilnacipran Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Linezolid	Major	Synergy	Coadministration of linezolid with serotonergic agents may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal…	52 sources — open the full entry
Lithium Carbonate	Major	Synergy	Lithium may enhance the pharmacologic effects of selective serotonin reuptake inhibitors (SSRIs) and potentiate the risk of serotonin syndrome, which is a rare…	28 sources — open the full entry
Maprotiline Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Mavacamten	Major	Metabolism	Coadministration with moderate to potent inhibitors of CYP450 2C19 or potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of…	1 sources — open the full entry
Milnacipran Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	102 sources — open the full entry
Mirtazapine	Major	Metabolism	Concomitant use of agents with serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs) and other antidepressants may potentiate the risk…	40 sources — open the full entry
Neratinib Maleate	Major	Metabolism	Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of neratinib, which is primarily…	7 sources — open the full entry
Nortriptyline	Major	Metabolism	Coadministration with fluvoxamine may significantly increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is…	25 sources — open the full entry
Ondansetron	Major	Synergy	Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs)…	16 sources — open the full entry
Palonosetron	Major	Synergy	Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors (SSRIs)…	16 sources — open the full entry
Paracetamol + Tramadol Hydrochloride	Major	Metabolism · Synergy · Unknown	Due to its serotonergic activity, coadministration of tramadol with selective serotonin reuptake inhibitors (SSRIs) may potentiate the risk of serotonin…2 documented mechanisms	34 sources — open the full entry
Pentazocine	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Pethidine Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry
Pirfenidone	Major	Metabolism	Coadministration with potent inhibitors of CYP450 1A2 may significantly increase the plasma concentrations of pirfenidone, which is primarily (70% to 80%)…	8 sources — open the full entry
Ramelteon	Major	Metabolism	Coadministration with fluvoxamine may significantly increase the plasma concentrations and pharmacologic effects of ramelteon. The mechanism is fluvoxamine…	6 sources — open the full entry
Ranolazine	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because…	4 sources — open the full entry
Rasagiline	Major	Synergy	By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors…	32 sources — open the full entry
Remifentanil Hydrochloride	Major	Synergy	Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…	100 sources — open the full entry

Food & lifestyle

alcohol
Moderate
Synergy
Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
What to do: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
4 sources
1. Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7
2. Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc. (1990):
3. "Product Information. Fycompa (perampanel)." Eisai Inc (2012):
4. "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc (2015):

Conditions

Conditions in which Fluvoxamine Maleate needs care, as documented in this source.

Depressive Disorder
Major
Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes. Families and caregivers should be advised of the need for close observation and communication with the treating physician. Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset. It may be prudent to refrain from dispensing large quantities of medication to these patients.
6 sources
1. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
2. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
3. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
4. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
5. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
6. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
Blood Platelet Disorders
Moderate
The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function. Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported. Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.
18 sources
1. Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412
2. Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949
3. Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8
4. Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9
5. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
6. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
7. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
8. Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30
Show all 18 sourcesShow fewer sources
1. Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2
2. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
3. Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132
4. Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6
5. Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8
6. Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4
7. Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5
8. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
9. Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30
10. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42
Epilepsy
Moderate
Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy. Therapy with SSRIs should be administered cautiously in patients with seizure disorders.
21 sources
1. Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992): 236-9
2. Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988): 46-51
3. Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991): 952-61
4. Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992): 604-24
5. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
6. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
7. Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992): 61-6
8. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
Show all 21 sourcesShow fewer sources
1. Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30
2. Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994): 145-6
3. Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994): 383-4
4. Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994): 127-38
5. Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993): 321
6. Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991): 433-5
7. Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994): 387-95
8. Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992): 48-53;disc. 53-4
9. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
10. Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995): 1238-9
11. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
12. Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000): 1276-8
13. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
Hyponatremia
Moderate
Treatment with SSRI antidepressants can cause hyponatremia. Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.
6 sources
1. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
2. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
3. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
4. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
5. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
6. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
Inappropriate ADH Syndrome
Moderate
The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention. SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy. Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH. Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.
35 sources
1. Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983): 708-10
2. Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991): 542-3
3. Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990): 1569-70
4. Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990): 948-9
5. Kazal LA, Jr Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993): 341-3
6. Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993): 1564
7. Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993): 723-4
8. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
Show all 35 sourcesShow fewer sources
1. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
2. Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993): 143
3. Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992): 1332
4. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
5. Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994): 779-80
6. Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994): 85-6
7. Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993): 62-3
8. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
9. Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994): 543-4
10. Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995): 809
11. Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995): 809-10
12. Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995): 390
13. Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996): 524
14. Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996): 680-3
15. "Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996): 562
16. Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996): 885
17. Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996): 1413
18. Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997): 108-10
19. Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997): 580
20. Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997): 93-5
21. Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997): 306-7
22. Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996): 519-27
23. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
24. Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30
25. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
26. Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003): 1694-702
27. Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006): 142-5
Liver Diseases
Moderate
Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver. The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function. Dosage adjustments may be necessary in accordance with the individual product package labeling.
17 sources
1. Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988): 353-9
2. Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988): 46-51
3. Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991): 952-61
4. Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992): 604-24
5. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
6. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
7. Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982): 351-7
8. Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989): 91-2
Show all 17 sourcesShow fewer sources
1. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989): 60-75
2. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
3. Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986): 313-34
4. Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993): 895-924
5. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
6. Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994): 1359-69
7. van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993): 203-20
8. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
9. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
Mania
Moderate
Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania. The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs. Patients with bipolar disorder are generally more likely to experience mania from antidepressants. Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder. Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.
27 sources
1. Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992): 1282-3
2. Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991): 1751
3. Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991): 1404
4. Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990): 1569
5. Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992): 107
6. Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991): 952-61
7. Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992): 604-24
8. Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987): 1513-4
Show all 27 sourcesShow fewer sources
1. Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993): 689-90
2. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
3. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
4. Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992): 61-6
5. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
6. Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993): 698-9
7. Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30
8. Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994): 549-50
9. Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991): 1263-4
10. Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993): 1455-7
11. Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994): 387-95
12. Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992): 48-53;disc. 53-4
13. Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991): 391-2
14. Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994): 78-9
15. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
16. Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995): 1238-9
17. Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996): 425-7
18. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):
19. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals (2002):
Weight Loss
Minor
The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss. Anorexia may occur in approximately 5% to 10% of patients. Weight change should be monitored during therapy if an SSRI is used in these patients.
11 sources
1. Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992): 1113-4
2. "Product Information. Zoloft (sertraline)." Roerig Division (2001):
3. "Product Information. Prozac (fluoxetine)." Dista Products Company (2001):
4. "Product Information. Paxil (paroxetine)." GlaxoSmithKline (2001):
5. Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994): 118-9
6. Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994): 1176-81
7. Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988): 948-9
8. Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992): 48-53;disc. 53-4
Show all 11 sourcesShow fewer sources
1. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc (2001):
2. Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994): 1350-2
3. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals (2001):

Therapeutic duplication

Drug classes that overlap with Fluvoxamine Maleate, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Fluoxetine/olanzapine
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Limbitrol ds
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Amitriptyline/perphenazine
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Bupropion/naltrexone
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Bupropion/dextromethorphan

Medicines

Food & lifestyle

alcohol

Conditions

Depressive Disorder

Blood Platelet Disorders

Epilepsy

Hyponatremia

Inappropriate ADH Syndrome

Liver Diseases

Mania

Weight Loss

Therapeutic duplication

antidepressants

antidepressants

antidepressants

antidepressants

antidepressants